NuVasive files IDE
This article was originally published in The Gray Sheet
Executive Summary
IDE filed for NeoDisc cervical nucleus replacement device, the company announces Oct. 24, increasing the device's odds of being the first of its kind to market. NuVasive acquired NeoDisc from AMI Holding's subsidiary Pearsalls in August. The firm plans to market NeoDisc with its Cerpass cervical total disc replacement, for which it filed an IDE in July. NuVasive expects that NeoDisc could reach the U.S. market in 2010 (1"The Gray Sheet" Aug. 8, 2005, p. 15)...
You may also be interested in...
Earnings Calls In Brief
NuVasive: CEO Alexis Lukianov predicts that the firm will break even by the end of 2006 following a strong third quarter. During a Q3 conference call, Lukianov announced that the firm had raked in $15.1 mil. in revenue, up 48% from the prior-year period. After launching several spinal implants and instrument products during the quarter, the firm is developing a direct sales force to replace its distributors. NuVasive is now 30% represented by direct reps, up from 21% in Q2, and hopes to reach at least 80% by mid-2006. The firm filed an IDE for its NeoDisc cervical nucleus replacement device at the end of October, putting it on track for a 2010 launch (1"The Gray Sheet" Oct. 31, 2005, In Brief)...
NuVasive Nabs Nucleus Replacement Device With $43.5 Mil. Pearsalls’ Buy
NuVasive expects its cervical nucleus-replacement device to be the first of its kind on the U.S. market in 2010, following its $43.5 mil. purchase of Pearsalls' intellectual property portfolio
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.